Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482957 · ClinicalTrials.gov registry record
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
A clinical trial of Sarcoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 2,100
- Enrollment target
- 1
- Study location
NCT06482957: Recruiting study of Sarcoma, sponsored by Vanderbilt-Ingram Cancer Center.
NCT06482957 is a study of Sarcoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 2,100 participants, above the 904-participant average among 122 other Sarcoma trials with a reported enrollment target (132% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06482957, a study of Sarcoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 2,100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.
Primary Outcome
Medical record review of Common Terminology Criteria for Adverse Events (CTCAEs)
Conditions Studied
Interventions
- OTHER Urine Collection
- OTHER Blood Collection
- OTHER Surveys
- OTHER Saliva Collection
- OTHER Stool Collection
Study Locations (1)
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2029-04 |
What NCT06482957 shows while recruiting
NCT06482957 is an observational study that tracks outcomes without assigning an intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 904-participant average among 122 other Sarcoma trials with a reported enrollment target (132% higher).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Urine Collection is the first listed.
NCT06482957 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06482957 about?
NCT06482957 is a clinical study titled "Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan". This study evaluates the impact that a sarcoma diagnosis and treatment have had on patients over time.
What is the current status of trial NCT06482957?
This trial is currently recruiting. The enrollment target is 2,100 participants. The study started on 2022-04-01. Estimated completion is 2029-04.
What conditions does trial NCT06482957 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT06482957?
The interventions under investigation include: Urine Collection (OTHER), Blood Collection (OTHER), Surveys (OTHER), Saliva Collection (OTHER), Stool Collection (OTHER).
Who is sponsoring clinical trial NCT06482957?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482957 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06482957's enrollment target sits among peer trials
2,100 8th of 122 higher than 115 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Enhanced Recovery After Surgery in Extremity Sarcoma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy